The balanced triple-agonist profile is hypothesized to combine glycemic control (GLP-1/GIP) with increased energy expenditure (glucagon) in metabolic research models
doi: 10.1016/j.metabol.2010.02.007 29 De SilvaVASuraweeraCRatnatungaSSDayabandaraMWanniarachchiNHanwellaR
Studies show patients taking semaglutide maintain their weight loss for a year after stopping treatment
The only current exceptions are Rybelsus , an oral pill for type 2 diabetes, and, recently in 2026, Wegovy the first oral GLP-1 drug available for weight loss
However, these pharmacies are still able to sell the compounded semaglutide that they made before May 22, 2025, up until the expiration date listed on the vial
Step 1: determine your last semaglutide dose Take your final dose of semaglutide on your regular injection day